Elekta announced that its solution for proton therapy, Monaco treatment planning for protons, has received 510(k) clearance from the U.S. Food and Drug Administration. Monaco brings robust functionality for proton therapy, featuring fast optimization and calculation via the Monte Carlo algorithm and user-configurable templates for different body sites to enable rapid proton plan creation. Monaco is a component of Elekta's Treatment Management Solution, which provides a full-featured environment for delivering proton therapy. Elekta was among the first companies to support proton therapy with treatment planning and oncology information systems. The company has built on this proven history to bring high quality planning, combined with intelligent, automated oncology workflows. The partnership with IBA, a world leader in proton therapy, provides a very strong foundation with an unmatched track record of over 100,000 patients treated by IBA's clinical partners. By harnessing Elekta's oncology informatics infrastructure, users can benefit from department-wide integration and standardized workflows. All radiotherapy machines, including linear accelerators and proton systems, will be connected, thus optimizing efficiency. This infrastructure also gives clinicians powerful analytics tools to go beyond standard efficiency improvements, using the wealth of data that the department generates to pinpoint improvements within processes. Overall, this contributes to higher productivity and cost reduction, and enables value-based healthcare.